202 related articles for article (PubMed ID: 29328476)
21. The urokinase plasminogen activator: an interesting way to improve myoblast migration following their transplantation.
El Fahime E; Mills P; Lafreniere JF; Torrente Y; Tremblay JP
Exp Cell Res; 2002 Nov; 280(2):169-78. PubMed ID: 12413883
[TBL] [Abstract][Full Text] [Related]
22. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
Ji F; Chen YL; Jin EY; Wang WL; Yang ZL; Li YM
World J Gastroenterol; 2005 Jun; 11(21):3222-6. PubMed ID: 15929171
[TBL] [Abstract][Full Text] [Related]
23. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
Moreau M; Mourah S; Dosquet C
Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
[TBL] [Abstract][Full Text] [Related]
24. Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.
Banyard J; Chung I; Migliozzi M; Phan DT; Wilson AM; Zetter BR; Bielenberg DR
BMC Cancer; 2014 May; 14():387. PubMed ID: 24885350
[TBL] [Abstract][Full Text] [Related]
25. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY
Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915
[TBL] [Abstract][Full Text] [Related]
26. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines.
Heikkilä P; Teronen O; Moilanen M; Konttinen YT; Hanemaaijer R; Laitinen M; Maisi P; van der Pluijm G; Bartlett JD; Salo T; Sorsa T
Anticancer Drugs; 2002 Mar; 13(3):245-54. PubMed ID: 11984068
[TBL] [Abstract][Full Text] [Related]
28. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
29. Resveratrol reduces TNF-α-induced U373MG human glioma cell invasion through regulating NF-κB activation and uPA/uPAR expression.
Ryu J; Ku BM; Lee YK; Jeong JY; Kang S; Choi J; Yang Y; Lee DH; Roh GS; Kim HJ; Cho GJ; Choi WS; Kim N; Kang SS
Anticancer Res; 2011 Dec; 31(12):4223-30. PubMed ID: 22199285
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of uPA/uPAR inhibits intermittent hypoxia-induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells.
Gupta R; Chetty C; Bhoopathi P; Lakka S; Mohanam S; Rao JS; Dinh DE
Int J Oncol; 2011 Mar; 38(3):733-44. PubMed ID: 21181094
[TBL] [Abstract][Full Text] [Related]
31. The expression of urokinase-related genes in superficial and invasive transitional cell carcinoma.
McGarvey TW; Kariko K; Barnathan ES; Thomas J; Malkowicz SB
Int J Oncol; 1998 Jan; 12(1):175-80. PubMed ID: 9454902
[TBL] [Abstract][Full Text] [Related]
32. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
33. CD44 stimulation by fragmented hyaluronic acid induces upregulation of urokinase-type plasminogen activator and its receptor and subsequently facilitates invasion of human chondrosarcoma cells.
Kobayashi H; Suzuki M; Kanayama N; Nishida T; Takigawa M; Terao T
Int J Cancer; 2002 Dec; 102(4):379-89. PubMed ID: 12402308
[TBL] [Abstract][Full Text] [Related]
34. Non-thermal atmospheric pressure plasma inhibits thyroid papillary cancer cell invasion via cytoskeletal modulation, altered MMP-2/-9/uPA activity.
Chang JW; Kang SU; Shin YS; Kim KI; Seo SJ; Yang SS; Lee JS; Moon E; Lee K; Kim CH
PLoS One; 2014; 9(3):e92198. PubMed ID: 24667444
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
36. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.
Bauer TW; Fan F; Liu W; Johnson M; Parikh NU; Parry GC; Callahan J; Mazar AP; Gallick GE; Ellis LM
Ann Surg; 2005 May; 241(5):748-56; discussion 756-8. PubMed ID: 15849510
[TBL] [Abstract][Full Text] [Related]
37. Fisetin inhibits migration and invasion of human cervical cancer cells by down-regulating urokinase plasminogen activator expression through suppressing the p38 MAPK-dependent NF-κB signaling pathway.
Chou RH; Hsieh SC; Yu YL; Huang MH; Huang YC; Hsieh YH
PLoS One; 2013; 8(8):e71983. PubMed ID: 23940799
[TBL] [Abstract][Full Text] [Related]
38. Secretion of macrophage urokinase plasminogen activator is dependent on proteoglycans.
Pejler G; Winberg JO; Vuong TT; Henningsson F; Uhlin-Hansen L; Kimata K; Kolset SO
Eur J Biochem; 2003 Oct; 270(19):3971-80. PubMed ID: 14511379
[TBL] [Abstract][Full Text] [Related]
39. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
40. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
